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Original Investigation | Public Health
Accelerometer- and Pedometer-Based Physical Activity Interventions
Among Adults With Cardiometabolic Conditions
A Systematic Review and Meta-analysis
Alexander Hodkinson, PhD; Evangelos Kontopantelis, PhD; Charles Adeniji, MD; Harm van Marwijk, PhD; Brian McMillan, PhD; Peter Bower, PhD; Maria Panagioti, PhD
Abstract
IMPORTANCE Accelerometers and pedometers are accessible technologies that could have a role
in encouraging physical activity (PA) in line with current recommendations. However, there is no solid
evidence of their association with PA in participants with 1 or more cardiometabolic conditions such
as diabetes, prediabetes, obesity, and cardiovascular disease.
OBJECTIVES To assess the association of accelerometer- and pedometer-based interventions with
increased activity and other improved health outcomes in adults with cardiometabolic conditions
and to examine characteristics of the studies that could influence the association of both
interventions in improving PA.
DATA SOURCES Records from MEDLINE, Embase, the Cochrane Central Register of Controlled
Trials, the Cumulative Index to Nursing and Allied Health, and PsycINFO were searched from
inception until August 2018 with no language restriction.
STUDY SELECTION Randomized clinical trials or cluster randomized clinical trials evaluating the use
of wearable technology devices such as pedometers and accelerometers as motivating and
monitoring tools for increasing PA were included. After removing duplicates, the searches retrieved
5762 references. Following abstract and title screening of 1439 references and full-text screening of
107 studies, 36 studies met inclusion criteria.
DATA EXTRACTION AND SYNTHESIS Mean difference in PA was assessed by random-effects meta-
analysis. Where the scale was different across studies, the standardized mean difference was used
instead. Heterogeneity was quantified using the I2 statistic and explored using mixed-effects
metaregression. This study was registered with PROSPERO and followed the Preferred Reporting
Items for Systematic Reviews and Meta-analyses (PRISMA) reporting guideline.
MAIN OUTCOMES AND MEASURES The primary outcome was objectively measured PA in the
short to medium term (postintervention to 8 months’ follow-up).
RESULTS Thirty-six randomized clinical trials (20 using accelerometers and 16 using pedometers)
involving 5208 participants were eligible for review. Meta-analysis involving 32 of these trials (4856
participants) showed medium improvements in PA: accelerometers and pedometers combined vs
comparator showed a small significant increase in PA overall (standardized mean difference, 0.39
[95% CI, 0.28-0.51]; I2 = 60% [95% CI, 41%-73%]) in studies of short to medium follow-up over a
mean (SD) of 32 (28.6) weeks. Multivariable metaregression showed improved association with PA
for complex interventions that involved face-to-face consultation sessions with facilitators (β = 0.36;
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Abstract (continued)
95% CI, 0.17-0.55; P < .001) and pedometer-based interventions (β = 0.30; 95% CI,
0.08-0.52; P = .002).
CONCLUSIONS AND RELEVANCE In this study, complex accelerometer- and pedometer-based
interventions led to significant small to medium improvements in PA levels of people with
cardiometabolic conditions. However, longer-term trials are needed to assess their performance over
time. This study found no evidence that simple self-monitored interventions using either
pedometers or accelerometers are associated with improvements in PA.
JAMA Network Open. 2019;2(10):e1912895. doi:10.1001/jamanetworkopen.2019.12895
Retracted on December 18, 2020
Introduction
A large proportion of the population experiences cardiometabolic conditions such as type 2 diabetes,
prediabetes states (eg, obesity), and cardiovascular disease.1,2 In the United Kingdom, 3.3 million
people have been diagnosed with type 2 diabetes and most of them experience additional
cardiometabolic conditions or risks, including obesity, increased blood pressure, disturbed blood lipid
levels, and a tendency to develop thrombosis and cardiovascular disease.3 The increasingly high
prevalence of cardiometabolic conditions combined with demographic changes means that the costs
of cardiometabolic disease will account for more than 20% of the entire UK National Health Service
(NHS) budget in the next 20 years, and most of these costs are avoidable.4
Despite their detrimental health and economic impacts, cardiometabolic conditions are mainly
lifestyle related and can be improved by targeting unhealthy lifestyle behaviors. In particular, low
physical activity (PA) is a fundamental modifiable risk behavior for people with cardiometabolic
conditions and a major opportunity for intervention.5 Addressing very low levels of PA has the
potential to prevent premature death more than any other risk factor,6 including smoking, alcohol
use, or stress-related illness. Recognizing its importance, several public health guidelines recommend
reaching and maintaining health-enhancing levels of PA7 and promote PA interventions in the
community and the workplace.8-10 However, promoting PA in people with cardiometabolic
conditions remains a challenge.11
Objective monitoring devices may help people with cardiometabolic conditions improve their
PA levels and health behaviors. These devices include simple monitoring devices such as pedometers
(step count devices whose results can be recorded daily in a log book) or accelerometers (more
technologically advanced devices containing time-based movement sensors, monitors of time and
intensity of activity and inactivity, and monitors of heart rate and calories burned). These devices
have recently become very popular for motivating, monitoring, and increasing PA in people with a
range of chronic conditions, including those with cardiometabolic conditions.12 Both types of devices
are simple, relatively inexpensive, user friendly, and potentially motivational.13
The first systematic review published more than a decade ago pooled the results of 8 trials
involving outpatient participants with mixed conditions (ie, diabetes, chronic obstructive pulmonary
disease, sedentary lifestyle, hypertension). Their results showed that pedometer-based
interventions had a promising association with PA levels.14 A more recent systematic review that
exclusively focused on people with type 2 diabetes identified 12 trials and showed that the use of
monitoring devices was associated with a medium short-term increase in PA.15 However, one major
limitation in the current evidence base is that the large overlap among cardiometabolic conditions
(eg, diabetes, obesity, and cardiac disease) has not been taken into consideration. For example, the
prevalence of adults with type 2 diabetes associated with overweight or obese status is
approximately 90% in the United Kingdom.16 Therefore, it is important to summarize the evidence
across people who experience 1 or more of these cardiometabolic conditions. The advantage of this
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broader approach is that a more robust investigation of specific factors that are potentially
responsible for the improved PA levels in the intervention groups is feasible (owing to the larger
number of eligible trials). For example, there is limited evidence about the role of intervention
components, delivery, and patient factors in increasing PA and improving health outcomes. There is
also no evidence, to our knowledge, on whether any PA benefits are sustained long term. These are
major barriers for the wider use of these monitoring devices in the care of people with
cardiometabolic conditions.
To our knowledge, the study described in this article is the most comprehensive systematic
review with meta-analysis to date examining whether interventions using monitoring devices
(pedometers and/or accelerometers) are associated with improvements in PA levels and health
outcomes, including blood glucose levels, blood pressure, cholesterol levels, body weight, and body
mass index (BMI) among people with cardiometabolic conditions. We also used metaregression to
examine whether the increased PA levels in the intervention groups over comparators were
moderated by the characteristics of interventions (type of monitoring device, setting daily goals, use
of consultations with facilitators, evaluation length, use of a theoretical framework, and uptake rate)
and patients (sex and index condition).
Methods
The review was conducted and reported in accordance with the Cochrane Handbook17 and the
Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) reporting guideline.18
The protocol was registered on PROSPERO (CRD42018104448).
Search Methods
Searches were performed in the Cochrane Central Register of Controlled Trials, Cumulative Index to
Nursing and Allied Health, Embase, MEDLINE, and PsycINFO from inception until August 2018 with
no language restriction. Search updates were performed in August 2019 and no further eligible
studies were identified. We used combinations of Medical Subject Headings terms and text words in
“diabetes,” “obesity,” “cardiovascular disease,” “pedometers,” “accelerometers” and “step-
counters.” The full search strategy in MEDLINE is available in eTable 1 in the Supplement. Additional
studies were obtained from screening the reference lists of included trials and previous systematic
reviews. We also contacted experts in the field to inquire about unpublished studies. Trial registers
(ClinicalTrials.gov, ISRCTN, the World Health Organization International Clinical Trials Registry
Platform portal, and OpenTrials.net) were also searched to identify any unpublished or ongoing trials.
Eligibility Criteria
Population
Eligible individuals included adults (aged 18 years) with a diagnosis of type 2 diabetes (or at risk for
type 2 diabetes), obesity or overweight, and cardiovascular disease. For obesity classification, the
World Health Organization definition was used to standardize across studies.19 We excluded studies
of people diagnosed with stroke and studies of people immediately after surgery.
Intervention
Randomized clinical trials (RCTs) or cluster RCTs evaluating the use of monitoring devices such as
pedometers and accelerometers as motivating and monitoring tools for increasing PA were included.
We excluded trials that required participants to be hospitalized, trials in which assessors were not
blinded to the wearable technology, and trials that used a wearable technology to measure the
association of a pharmacological treatment with an individual’s ability to be physically active.
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Comparator
Any comparator (eg, usual care, control, no intervention, or a minimal intervention with step
counters used only for counting steps) was included. All comparators were treated the same in the
analysis; however, a sensitivity analysis was performed for usual care groups only.
Outcome
The primary outcome was objectively measured PA levels in the short term (eg, postintervention to
6 months’ follow-up). Secondary outcomes were long-term levels of PA, self-reported PA, body
weight (kilograms) or BMI (calculated as weight in kilograms divided by height in meters squared),
blood glucose level (hemoglobin A1c [HbA1c] percentage), blood pressure (systolic or diastolic
[millimeters of mercury]), and cholesterol levels (total, high-density lipoprotein, and low-density
lipoprotein [milligrams per deciliter]). Studies were excluded if they only measured secondary
outcomes.
Data Collection and Extraction
Titles and abstracts were assessed by 3 of us (A.H., M.P., and C.A.). Data extraction was conducted by
1 of us (A.H.) and checked by a second reviewer (C.A.) for consistency. A modified version of the
Cochrane Public Health Group’s data extraction template20 was used after pilot testing on 5 studies
to ensure reliability. We used the Oxford Implementation Index to assess implementation of the
intervention and contextual factors.21 This was adapted for the purposes of this review.
Assessment of Risk of Bias
Risk of bias for each study was assessed by 2 of us (A.H. and C.A.) using the Cochrane Risk of Bias
tool.22 The blinding of participants and personnel was not included in the risk of bias assessment, as
many studies did not report this domain as it was not possible to blind participants while using the
technology device. If further information was required on any aspect of study design or outcome, we
sought related publications and trial protocols and contacted study authors. For cluster RCTs, the
Cochrane handbook section 16.3.2 was consulted.
Missing Data
Study authors were contacted by email where there were missing or unclear data (eg, relating to the
primary outcome). Studies for which insufficient primary data were available (eg, missing data
cannot be obtained) were excluded from the meta-analysis but not the review.
Data Synthesis and Analysis
The statistical analysis proceeded in 2 stages. First, DerSimonian-Laird inverse variance weighting
random-effects meta-analyses23 were conducted to determine the association of the interventions
with improved primary and secondary outcomes compared with controls. If the control group varied
considerably, we performed a sensitivity analysis for just the usual care group. For dichotomous
outcomes, relative risks and their 95% confidence intervals were calculated, and for continuous
outcomes, standardized mean differences (SMDs) were calculated using the Hedges g.24 The SMDs,
or associations, were interpreted according to the Cohen rule of interpretation.25 Physical activity
outcomes were separated by intervention measure, ie, objectively (daily step count for pedometers,
moderate-to-vigorous PA [MVPA] and total PA for accelerometers) or self-reported. For studies that
included both interventions (ie, both steps and MVPA as outcome measures), we applied a
conservative approach by pooling the overall PA measure by halving the number of patients in both
groups for both outcomes. Pooled associations with 95% confidence intervals are presented, and
forest plots with I2 (with test-based 95% confidence intervals)26 are used to display statistical
heterogeneity between studies. Where a study contributed more than 1 intervention group to the
analysis, we combined them while avoiding double counting of the control group. For cases in which
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there were insufficient data to include in meta-analyses, we synthesized these narratively in
the results.
Second, mixed-effects univariable and multivariable (multilevel) metaregression analyses were
conducted in R statistical software version 3.4.3 (R Project for Statistical Computing) to examine the
influence of a number of study-level covariates on the pooled association with the primary outcome
(PA levels). The multilevel aspect of the regression model allows for potential clustering by including
random effects for both intervention and study. Eight covariates were selected and coded following
consensus procedures and informed by the Oxford Implementation Index: sex (100% female vs
mixed sex), age (50 years), index condition (ie, type 2 diabetes, overweight or obese,
cardiovascular disease), type of device, consultations with facilitators, intervention length, goal set
for PA, theory-based intervention, and intervention uptake. Results were considered statistically
significant at P < .15 using 2-tailed tests. Covariates meeting our significance criterion were entered
into a multivariable metaregression model. The P < .15 threshold was conservative to avoid
prematurely discounting potentially important explanatory variables, and adjusted tests were used
for controlling type I error.27 All analyses were performed in the R version 3.4.3. For each meta-
analysis with 10 studies or more, funnel plots, Begg test, and Egger test were used to examine
potential publication bias. The trim-and-fill method was used as a sensitivity analysis to observe
factors associated with publication bias.
Results
After removing duplicates, the search retrieved 5762 references. Following abstract and title
screening of 1439 references and full-text screening of 107 studies, 36 studies met our inclusion
criteria (20 studies using accelerometers and 16 studies using pedometers) (Figure 1). No
unpublished studies were identified.
Figure 1. Flow Diagram of Screening Stages
107 Full-text articles assessed for eligibility
1439 Records screened (title and abstract) after duplicates removed
5762 Records identified from citation searching 
395 Records mapped to confirm eligibility criteria
36 Studies included in review
32 Studies included in meta-analysis
1044 Records excluded
288 Records excluded
71 Full-text articles excluded
37 Population
8 Active control group
13 Other physical activity measures
9 Diet and physical activity combined
4 Not RCT
No unpublished studies were found. RCT indicates
randomized clinical trial.
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Characteristics of Included Studies
Location, Setting, and Participant Characteristics
Most studies were conducted in either the United States (9 studies) or the United Kingdom (6
studies). The settings of the studies varied and included hospitals, primary care, medical and
community centers, and universities. The 36 studies involved 5208 participants (eTable 2 in the
Supplement). Most studies included adults with a mean age between 32 and 71 years, with 13 studies
focusing on older adults with a mean age older than 60 years. Four studies28-31 included women only
and the remainder involved both sexes. The target populations recruited in the studies were
predominantly those diagnosed with type 2 diabetes (16 studies), but others included cardiovascular
diseases (13 studies) and obese or mixed obese and overweight participants (7 studies).
Intervention Characteristics
The interventions mainly focused on increasing PA, preventing disease, and managing weight
(eTable 3 in the Supplement). Nine studies used a theoretical framework consisting of social cognitive
approaches (eg, health belief model, theory of planned behavior, or transtheoretical model);
however, behavior change outcomes did not appear to have been captured in their results. Fewer
than one-third of the studies (12 trials) tested simple pedometer or accelerometer interventions (ie,
after an initial consultation session, patients were provided with the accelerometer or pedometer
and a log book to self-monitor their outcomes using written instructions with no additional support
by facilitators or health care professionals), whereas 24 studies tested more complex interventions
that also involved consultation sessions (ie, patients were supported by facilitators who were mainly
health professionals via face-to-face consultations and/or telecommunications during the
intervention). The median (range) duration for receiving the intervention was 7 months (2 weeks to
4 years), indicating considerable variation in duration. The mean (SD) follow-up was 32 (28.6) weeks.
Risk of Bias
The quality of the studies was variable (eFigure 1 in the Supplement). Twenty-two studies (61%) had
a low risk of bias for the random sequence generation, and 15 studies (42%) had low risk for allocation
concealment. Only 2 studies (6%)32,33 were deemed high risk for this criterion. Similarly, blinding of
outcome assessment was moderately reported, with 19 studies (53%) showing low risk; however, 7
studies (19%) reported high risk for this domain. Criteria for incomplete outcome data were mostly
satisfied across studies, displaying low risk in 23 studies (64%); however, 7 studies (19%) reported
high risk. For selective reporting, only 2 studies (6%)17,34 exhibited high risk of bias.
Association of the Interventions With PA
Primary Outcome: PA Improvement
Twenty-two of the 36 studies were included in the meta-analysis (4856 participants). Summary
estimates from the meta-analyses are presented in Table 1. Across all studies involving interventions
with monitoring devices vs comparators there was a small to medium significant increase in PA over
approximately an 8-month period (SMD, 0.39 [95% CI, 0.28-0.51]; I2 = 60% [95% CI, 41%-73%])
(eFigure 2 in the Supplement). Accelerometer-based interventions demonstrated a small increase in
PA compared with comparators (SMD, 0.30; 95% CI, 0.16-0.44; n = 20 studies), and pedometer-
based interventions demonstrated a medium increase of PA compared with comparators (SMD, 0.52;
95% CI, 0.32-0.72; n = 15) (eFigure 3 in the Supplement). For pedometer-based interventions, the
PA measures translated to 1702.85 steps per day (95% CI, 1066.67-2339.03 steps per day) for
intervention vs the usual care group. This value is generally lower than recommendations set out by
governments and agencies globally. Heterogeneity was high for pedometer use (I2 = 72% [95% CI,
53%-83%]) and moderate for accelerometer use (I2 = 52% [95% CI, 20%-71%]). The cumulative plot
(eFigure 4 in the Supplement) of PA performance based on total session times showed that programs
with longer periods of engagement in PA generally performed better. However, 18 studies did not
report the length of the sessions and therefore could not be included.
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Moderators of Association With PA (Univariable and Multivariable Metaregression)
The results of the univariable and multivariable analyses are shown in Table 2. Interventions using
consultations with a health professional (β = 0.32; 95% CI, 0.10-0.55; P = .002), pedometer-based
interventions (β = 0.24; 95% CI, 0.004-0.48; P = .05), and the inclusion of predominately male




















20 3115 39 NA NA 0.30 (0.16 to 0.44) 52 (20 to 71)
Pedometer (No. of steps) 15 1741 23 1702.85 (1066.67 to
2339.03)
72 (53 to 83) 0.52 (0.32 to 0.72) 66 (41 to 80)
Glucose (hemoglobin A1c %) 13 1005 24 −0.25 (−0.45 to −0.06) 57 (20 to 77) NA NA
Accelerometer 3 207 39 −0.02 (−0.19 to 0.16) 0 (0 to 90) NA NA
Pedometer 10 798 20 −0.40 (−0.55 to −0.25) 10 (0 to 66) NA NA
Blood pressure, mm Hg
Systolic 15 1186 23 −0.42 (−2.27 to 1.43) 0 (0 to 54) NA NA
Diastolic 14 1093 23 −1.99 (−5.92 to 1.95) 89 (83 to 93) NA NA
Cholesterol, mg/dL
Total 10 874 26 NA NA −0.03 (−0.25 to 0.20) 52 (2 to 77)
High-density lipoprotein 7 735 33 NA NA 0.04 (−0.14 to 0.21) 16 (0 to 60)
Low-density lipoprotein 6 591 27 NA NA 0.01 (−0.16 to 0.18) 4 (0 to 76)
BMI 13 1168 21 −0.17 (−1.14 to 0.79) 65 (37 to 81) NA NA
Accelerometer 5 429 24 1.06 (−0.66 to 2.77) 66 (11 to 87) NA NA
Pedometer 8 739 20 −0.89 (−1.84 to 0.05) 45 (0 to 76) NA NA
Weight, kg 12 1061 20 0.18 (−2.82 to 3.19) 57 (18 to 77) NA NA
Accelerometer 5 367 18 2.14 (−1.55 to 5.84) 33 (0 to 75) NA NA
Pedometer 7 694 22 −1.43 (−5.64 to 2.79) 60 (8 to 83) NA NA
Abbreviations: BMI, body mass index (calculated as weight in kilograms divided by
height in meters squared); MD, mean difference; NA, not applicable; SMD, standardized
mean difference.
SI conversion factor: To convert cholesterol to mmol/L, multiply by 0.0259.
Table 2. Univariable and Multivariable Metaregressions for Physical Activity Outcomes
Covariate of Interest β (95% CI) P Value I2, % R2, %
Univariable
Intervention: pedometer vs accelerometer 0.24 (0.004 to 0.48) .05 55.84 13.91
Delivery: facilitated delivery vs self-reported 0.32 (0.10 to 0.55) .006 50.84 29.38
Cardiometabolic condition: type 2 diabetes
populations vs overweight/obese or
cardiovascular disease
0.16 (−0.09 to 0.41) .19 61.81 0.00
Sex: male vs female 0.25 (0.03 to 0.42) .03 57.32 8.18
Age: <50 y vs ≥50 y 0.003 (−0.37 to 0.38) .99 63.98 0.00
Intervention length ≤4 mo vs >4 mo −0.19 (−0.44 to 0.07) .15 58.87 10.13
Goal setting use: yes vs no −0.11 (−0.35 to 0.14) .40 59.17 0.00
Uptake ≥80% uptake vs <80% uptake −0.03 (−0.29 to 0.22) .80 64.28 0.00
Use of theoretical concept: yes vs no 0.0014 (−0.25 to 0.26) .99 61.89 0.00
Studies with low risk of bias: yes vs no 0.04 (−0.45 to 0.54) .58 62.55 4.28
Multivariable
Intervention 0.30 (0.08 to 0.52) .002 NA NA
Delivery 0.36 (0.17 to 0.55) <.001 NA NA
Sex 0.05 (−0.14 to 0.25) .58 NA NA
Model fit χ 23 = 17.46 <.001 Abbreviation: NA, not applicable.
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participants in studies (β = 0.25; 95% CI, 0.03-0.42; P = .03) were the only factors associated with
improved PA levels in the univariable regression analyses. The remaining factors, including index
diagnosis of participants, age of participants, length of the intervention, goal setting, underpinning
the intervention with a theoretical framework, intervention uptake, and risk of bias scores, were not
associated with PA level and were not eligible for inclusion in the multivariable regression analysis.
The overall multivariable model was statistically significant (χ 23 = 17.46; P < .001) and reduced the I
2
statistic from 70% to 46%. Both factors associated with improved PA, consultations with a health
professional (β = 0.36; 95% CI, 0.17-0.55; P < .001) and pedometer vs accelerometer (β = 0.30; 95%
CI, 0.08-0.52; P = .002), remained significant in the multivariable model. Thus, interventions
involving regular consultations by health professionals (compared with self-monitoring only) and
pedometer-based interventions (compared with accelerometers) were the main 2 factors associated
with improved PA levels.
We conducted a post hoc subgroup analysis using the variables of enhanced consultation and
monitoring device whereby studies17,29-32,35-62 were divided into 4 groups to best visualize the
results of metaregression analyses (Figure 2). Pedometer interventions incorporating consultations
with health professionals were associated with greater increases in PA (SMD, 0.73; 95% CI,
0.50-0.97; n = 10) and supervised accelerometer interventions were associated small to medium PA
increases (SMD, 0.29; 95% CI, 0.14-0.43; n = 12) vs comparators. In contrast, interventions without
consultations had a weaker association with PA for pedometers (SMD, 0.18; 95% CI, 0.07-0.29;
n = 5) and no association with PA for accelerometers (SMD, 0.28; 95% CI, −0.05 to 0.61; n = 8).
Secondary Outcomes
Interventions with monitoring devices were associated with small but statistically significant
reductions in blood glucose (HbA1c percentage) vs comparators (MD, −0.25%; 95% CI, −0.45% to
−0.06%; n = 13) (Table 1). Pedometer-based interventions were associated with the greatest
effectiveness (MD, −0.40; 95% CI, −0.55 to −0.25; n = 10), whereas accelerometer performance was
not significant across 2 studies. No association was found for systolic and diastolic blood pressure,
total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, BMI, and
weight. Other measures of PA, including self-reported PA, metabolic equivalents of tasks, and
activity times, were not significant (eFigure 5 in the Supplement).
Publication Bias
Publication bias was detected for pedometer and accelerometer use by visual inspection of the
funnel plots (eFigure 6 in the Supplement) and as indicated by Begg test (z = 3.301; P = .002) and
Egger test (z = 3.2484; bias coefficient, 1.64; 95% CI, 0.74-2.53; P = .001). The trim-and-fill method
was used to adjust for potential missing studies.
Narrative Synthesis
There were 4 pedometer studies that reported nonamenable data for meta-analysis; 2 studies30,31
reported a significant increase in number of steps and the other 2 studies34,63 reported no increase in
the number of steps between intervention groups.
Discussion
This systematic review and meta-analysis shows that both accelerometers and pedometers are
associated with small to medium improvements in PA among people with cardiometabolic
conditions. However, this association was only present over the short to medium term.
Metaregressions suggest that the type of device and consultations with health professionals appear
to be key factors associated with PA improvements obtained by these interventions. The greatest
increases in PA levels for people with cardiometabolic conditions were achieved by complex
interventions combining the use of pedometers with regular consultation sessions with a health
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Accelerometer + face to face
SMD
(95% CI)
0.513Baillot et al,43 2018 0.68 (–0.13 to 1.49)
1.330Christle  et al,32 2017 –0.12 (–0.62 to 0.39)
0.820Cowie et al,45 2011 0.39 (–0.23 to 1.02)



















NAFixed-effects model 0.20 ( 0.12 to 0.28)
2.969Frederix et al,51 2015 0.23 (–0.10 to 0.57)
0.519Guiraud et al,52 2012 1.17 (0.34 to 2.01)
2.192Kirk et al,57 2009 0.32 (−0.07 to 0.71)

















111.4 (156.0)Unick et al,40 2017 0.26 (0.00 to 0.52)
NA 35.0Random-effects model 0.29 ( 0.14 to 0.43)




1.635Devi et al,50 2014 0.01 (–0.44 to 0.47)
3.4121Greaney et al,29 2017 –0.12 (–0.43 to 0.19)
0.216Holliday et al,30 2018 1.01 (–0.27 to 2.30)













NAFixed-effects model 0.24 (0.07 to 0.40)
0.621Miyamoto et al,58 2017 0.22 (–0.53 to 0.98)
1.639Pekmezi et al,31 2017 0.21 (–0.24 to 0.66)








NA 22.1Random-effects model 0.28 (–0.05 to 0.61)
Heterogeneity: I2 = 71%; P <.01
Pedometer + self-managed
0.616Andersen et al,41 2015 0.51 (–0.25 to 1.27)
7.3174Dasgupta et al,47  2017 0.24 (0.03 to 0.45)
0.620Katzmarzyk et al,56 2011 0.21 (–0.51 to 0.94)
4.7115Reid et al,17 2012 0.19 (–0.07 to 0.45)
12.0294
12.0 5334.0 (2101.0)
173.0 5030.0 (3019.8) 
11.5 6637.0 (2558.2)
108.0 6750.0 (3366.0)







NAFixed-effects model 0.18 (0.07 to 0.29)619 581.5
NA 19.2Random-effects model 0.18 (0.07 to 0.29)
Heterogeneity: I2 = 0%; P = .83
Pedometer + face to face
0.515Araiza et al,42 2006 1.15 ( 0.37 to 1.93)
0.822Borland et al,44  2014 0.71 (0.08 to 1.33)
0.919Cupples et al,46 2013 0.36 (–0.24 to 0.95)













NAFixed-effects model 0.74 (0.55 to 0.92)
1.060De Greef et al,48 2011 0.44 (–0.12 to 0.99)
0.923Fayehun et al,37  2018 0.60 (0.00 to 1.19)
1.332Houle et al,53 2011; and
Houle et al,54 2012
0.55 (0.06 to 1.05)













NA 23.7Random-effects model 0.73 (0.50 to 0.97)
Heterogeneity: I2 = 37%; P =.11
NA 100.0Random-effects model 0.39 (0.28 to 0.51)
100.02643 2316.0Fixed-effects model 0.25 (0.19 to 0.31) NA
Heterogeneity: I2 = 60%; P <.01






































NA indicates not applicable; SMD, standardized mean difference.
a For studies using accelerometers, mean values reflect minutes of moderate-to-vigorous physical activity. For studies using pedometers, mean values reflect total daily steps.
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professional (face-to-face or remotely). For example, in a pedometer-based intervention with
additional support targeting patients with type 2 diabetes, Van Dyck and colleagues35 found that
increases in PA persisted in the medium term, with those in the intervention group reporting an
additional 2967 steps per day on average 1 year later. Accelerometer-based interventions had no
association with PA levels compared with comparators when simple self-monitoring was used
without additional consultations. Pedometers showed a small significant association with PA when
simple self-monitoring of the intervention was used compared with more complex delivered
interventions. For example, Yates and colleagues36 found that, at 12 months, those in the pedometer
group reported 383 more steps per day than the control group. Some evidence did show that more
complex interventions, enhanced with consultations and longer periods of PA engagement (with
longer or more sessions) did improve PA levels. However, 19 trials did not report the total PA
engagement time. Interventions were also associated with reduced HbA1c levels. For example, in an
intervention incorporating pedometers and clinician support, Fayehun et al37 found levels of HbA1c to
be significantly lower in the intervention group at an 11 week follow-up. Although the change across
all included studies was statically significant compared with usual care, the clinical relevance of the
magnitude of change was small (−0.25%). Other secondary health outcomes like blood pressure,
cholesterol levels, weight, and BMI showed results that were not statically significant.
Our findings are consistent with the results of earlier systematic reviews15,64 involving
populations at most risk, which suggests medium improvements in PA levels at short-term follow-up
assessments in response to pedometer- or accelerometer-based interventions. The most recent
review64 reported a medium increase in PA (SMD, 0.57; 95% CI, 0.24-0.91) but focused solely on
people with type 2 diabetes. Moreover, our extensive searches and broader eligibility criteria in terms
of population resulted in pooling PA outcomes from 32 studies, up to 3 times the number of RCTs
included in previous reviews. We have also assessed the association of several study-level factors
with PA improvements. Our analyses support the importance of complex interventions involving
consultation sessions with health professionals for boosting PA benefits for people with
cardiometabolic conditions. Furthermore, a recent review19 of consumer-based wearable activity
trackers in general populations indicated improved associations with PA levels but limited availability
of long-term follow-up data. While this study is related to our review with a focus on electronic
devices for monitoring PA, it focused on studies conducted among healthy general populations and
not those at risk for chronic conditions.
Strengths and Limitations
The major strength of this systematic review and meta-analysis is that we searched 5 major
databases for relevant literature and used well-established statistical methods, including pairwise
meta-analysis and multilevel multivariable metaregression, to explore the full association of
associated factors. However, there are also limitations. We performed metaregression to explore the
heterogeneity observed in the main analyses, but important uncertainties remain regarding risk of
bias assessments with many unclear domains, whereas participant characteristics such as age and
sex are based on aggregate data. Therefore, the metaregression results should be interpreted with
caution. Owing to the heterogeneous nature of the 13 cardiovascular disease trials studied and the
limited number of trials (7) that focused on overweight or obese participants, we chose to combine
the trials under the definition of a cardiometabolic condition. We included only those study
populations at risk; however, we understand that this is a potential limitation as studies that did not
explicitly report this type of population may have been missed. A network meta-analysis was not
performed because all the evidence comparing interventions with one another is reliant on indirect
evidence only; therefore, quantifying the change in PA was easier to assess in the pairwise analysis.
We initially planned to perform a bivariate meta-analysis estimating the overall correlation between
outcomes65; however, owing to the large within-study variation, we were not able to estimate
correlations for PA outcomes and were only able to look at outcomes for HbA1c levels, BMI, weight,
and cholesterol levels. Although we performed extensive searches to identify all relevant published
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and unpublished studies in both the ClinicalTrials.gov and OpenTrials.net databases, our formal tests
indicated small study bias, indicating publication bias. As recommended, we dealt with small study
bias using the trim-and-fill method. Also, we did not look at behavior change outcomes such as those
reported in line with the theoretical domains framework, as only 1 trial mentioned explicitly that such
outcomes would be collected.66
Implications for Future Research and Practice
We found that the use of accelerometers increased the levels of PA by approximately an SMD of 0.30
increase in MVPA and that pedometers increase steps per day by an SMD of 0.52 or an MD of 1703
steps per day among people with cardiometabolic conditions. These values are generally lower than
the recommendations of the most recent 2018 Physical Activity Guidelines Advisory Committee
Scientific Report20 by the US Department of Health and Human Services and other
recommendations set out by governments and agencies globally.67 For instance, the UK National
Obesity Forum classifies 3000 to 6000 steps per day as sedentary, Northern Ireland’s Public Health
Agency promotes an additional 3000 steps, and the America on the Move campaign suggests an
additional 2000 steps each day to stop weight gain. For accelerometers, public health guidelines
endorse 30 minutes (at times up to 60 minutes) per day (or 150-210 minutes per week) of MVPA,
typically in bouts of at least 10 minutes.68,69 This could not be assessed because the total MVPA
session times in minutes were rarely reported in the studies.
We found evidence that complex interventions that combine the use of monitoring devices
(particularly pedometers) with regular consultations with health professionals might be an effective
way of increasing PA and reaching the recommendations set out by governments and agencies for
people with cardiometabolic conditions. It is likely that giving feedback and lifestyle advice to
patients on a regular basis supported the effectiveness of these interventions. Several studies have
suggested positive associations of multimodal pedometer interventions with PA levels in a range of
populations, including those with type 2 diabetes and cardiac conditions,38 but this is the first study,
to our knowledge, to highlight the role of regular consultations in the association of pedometer
interventions with PA in people with cardiometabolic conditions. This finding warrants consideration
in future trials and further investigation using more robust methods such as individual participant
data meta-analyses. Moreover, we only found 2 studies that reported associations between
accelerometer or pedometer use and PA levels after a 1-year follow-up period.39,40 Long-term
follow-up assessments are needed to generate evidence regarding the sustainability of PA increases
over time. Such long-term assessments have a greater potential to affect outcome performance and
potentially explain more about the intervention program than current short-term assessments.
Conclusions
This systematic review found that, in participants with cardiometabolic conditions, the use of
monitoring devices increased the levels of PA by approximately 1703 steps per day (SMD = 0.52) and
increased MVPA by a SMD of 0.22. However, the evidence is only over a short to medium period.
Complex pedometer and accelerometer interventions that used complementary consultations with
health professionals appear to be the most promising in improving PA among people with
cardiometabolic conditions. Understanding the association between accelerometer- and pedometer-
based interventions and PA over the longer term could have major implications in the care of people
with cardiometabolic conditions.
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